Key Takeaway:
- The FDA proposes a Testosterone therapy labels update after new research found no significant increase in heart attack or stroke risk in eligible patients.
- Testosterone replacement therapy remains approved only for men with confirmed hypogonadism and is not an anti-aging treatment.
- Doctors continue to recommend careful screening and monitoring because risks such as blood clots, irregular heartbeat, and kidney injury may still occur.
The U.S. Food and Drug Administration is asking manufacturers to update testosterone replacement therapy labels after reviewing new clinical evidence that challenges some longstanding warnings while maintaining the need for careful medical oversight.
FDA revises longstanding testosterone warnings
The U.S. Food and Drug Administration is proposing changes to prescribing information for testosterone replacement therapy, saying newer clinical evidence no longer supports some warnings that have appeared on product labels for more than a decade.
The agency, through the U.S. Department of Health and Human Services, said the revisions follow a review of research completed since 2015, when manufacturers were required to warn that the safety and effectiveness of testosterone therapy had not been established for men with age-related or unexplained low testosterone.
Testosterone replacement therapy is approved for men with hypogonadism, a condition in which the body does not produce enough testosterone because of disorders affecting the testicles, pituitary gland, or hypothalamus. The treatment replaces the missing hormone but does not correct the underlying cause of low testosterone.
“FDA’s responsibility is to ensure prescribing information reflects the best available scientific evidence,” Michael Davis, acting director of the FDA’s Center for Drug Evaluation and Research, said in a press release. “These Testosterone therapy labels updates provide patients and healthcare professionals with clearer information about the benefits and risks of testosterone replacement therapy and support informed treatment decisions.”
Large studies shape FDA’s updated position
The FDA said recent evidence, including a clinical trial involving more than 5,200 men, found no meaningful increase in major cardiovascular events such as heart attack or stroke among patients receiving testosterone therapy.
Based on those findings, the agency said the available evidence no longer supports earlier label limitations regarding cardiovascular safety. The FDA is also requesting that testosterone therapy labels update to include prostate-related information after reviewing research that generally did not show an increased risk of prostate cancer among men using testosterone therapy.
Despite the proposed revisions, the agency continues to recommend prostate screening before treatment and ongoing monitoring during therapy. Testosterone products remain prescription medications intended for medically confirmed hormone deficiency rather than routine treatment for aging-related symptoms.
Experts continue to urge careful patient selection
Medical experts caution that the proposed label revisions do not expand approved uses for testosterone therapy or make it appropriate for every man experiencing fatigue, low libido, or reduced muscle mass.
According to Harvard Health Publishing, those symptoms may result from poor sleep, depression, chronic illness, medication side effects, or lifestyle factors rather than low testosterone.
The American College of Physicians continues to recommend that testosterone therapy labels update primarily for treating sexual dysfunction in men with age-related low testosterone and says evidence remains insufficient to support its use for improving energy or cognitive function.
Researchers behind a 2023 study published in the New England Journal of Medicine also reported higher rates of irregular heartbeat, blood clots and kidney injury among men receiving testosterone therapy, even though heart attack and stroke rates were not significantly higher.
Healthcare providers continue to recommend careful evaluation before starting therapy, particularly for patients at elevated risk of prostate cancer, severe urinary symptoms, or significant cardiovascular disease. They also emphasize that treatment should begin only after laboratory testing confirms clinically low testosterone and an underlying medical cause has been evaluated.
